Scotiabank lowered the firm’s price target on Syndax (SNDX) to $16 from $18 and keeps a Sector Perform rating on the shares. The firm adjusted its price target on the stock based on its revised market share estimates for ziftomenib in relapsed/refractory KMT2Ar acute lymphoblastic leukemia and front-line acute leukemia treatment settings, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX: